BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7478436)

  • 1. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study.
    Porta C; Moroni M; Nastasi G; Arcangeli G
    Oncology; 1995; 52(6):487-91. PubMed ID: 7478436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.
    André T; Colin P; Louvet C; Gamelin E; Bouche O; Achille E; Colbert N; Boaziz C; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Billiau V; Buyse M; Gramont A;
    Semin Oncol; 2001 Feb; 28(1 Suppl 1):35-40. PubMed ID: 11273588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
    Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
    Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
    J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
    Arkenau HT; Rettig K; Porschen R
    Int J Colorectal Dis; 2005 May; 20(3):258-61. PubMed ID: 15549327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer.
    Cure H; Chevalier V; Pezet D; Bousquet J; Focan C; Levi F; Garufi C; Chipponi J; Chollet P
    Anticancer Res; 2000; 20(6C):4649-53. PubMed ID: 11205195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site.
    Culine S; Ychou M; Fabbro M; Romieu G; Cupissol D
    Anticancer Res; 2001; 21(2B):1455-7. PubMed ID: 11396231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
    Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
    de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
    J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
    Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers.
    Yeh KH; Cheng AL; Lin MT; Hong RL; Hsu CH; Lin JF; Chang KJ; Lee PH; Chen YC
    Anticancer Res; 1997; 17(5B):3867-71. PubMed ID: 9427794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
    Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
    J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
    Copur MS; Capadano M; Lynch J; Goertzen T; McCowan T; Brand R; Tempero M
    J Clin Oncol; 2001 May; 19(9):2404-12. PubMed ID: 11331319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.